GET DAILY SIGNALSGMRS Stock: Analyst Consensus Points to $19 Target and +69% Upside
Key Takeaways
- The central target used here is $19, the arithmetic mean of eight verified Wall Street price targets, rounded from $18.88.
- The analyst price target range is wide — roughly $14 to $30 — reflecting genuine disagreement about the company's growth and deleveraging outlook.
- At a recent price near $11.27, reaching $19 would require an upside of roughly 69%, a very large move.
- Bullish analysts emphasize GMR's position as the largest U.S. emergency medical services (EMS) provider, durable pricing, and a path to higher margins.
- Key risks include ongoing GAAP net losses, elevated leverage, a high P/E (price-to-earnings) multiple, and a limited public trading history after the May 2026 IPO.
- You can explore more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings across dedicated pages.
- For additional signal-based ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
GMR Solutions, Inc. (GMRS), a provider of emergency medical services through subsidiaries such as Global Medical Response and its air ambulance operations, went public on the NYSE in May 2026. Eight credible analyst targets were reviewed to establish the central figure. Averaging them produces $18.88, which is rounded to a clean $19 central target.
The individual targets span a wide band. On the cautious side, Morgan Stanley's Craig Hettenbach set a $14 Equal-weight target. Barclays and J.P. Morgan (Benjamin Rossi, who raised his target from $15 to $16 in September 2026) both sit at $16. Citi's Daniel Grosslight initiated at $17, Bank of America's Joanna Gajuk at $18, while UBS and Evercore ISI are at $20. Goldman Sachs (Scott Fidel) carries the high end at $30, trimmed from $35 in August 2026.
The wide $14-to-$30 range reflects fundamentally different views. Analysts near the low end emphasize leverage and a need for financial improvement, while those at the top argue the market underappreciates the defensiveness and margin potential of a scaled EMS franchise. The average is a statistical midpoint, not a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock recently trading around $11.27 and a 52-week range of roughly $9.00 to $15.98, the move to $19 implies about a 69% gain — a very large advance that would take the shares well above their post-IPO high. The company reported quarterly revenue of about $1.49 billion and a GAAP net loss of roughly $28 million for the quarter ending June 30, 2026, underscoring that this is an early-stage, scale-heavy public story.
A path toward the target would likely depend on demonstrating margin expansion, reducing net debt, and converting revenue scale into consistent profitability. Because the stock carries a high trailing P/E and no dividend, investors are effectively pricing in future earnings recovery rather than current profits.
What Could Support a Move Toward the Target
Several factors underpin the more constructive targets. GMR is described by analysts as the largest EMS provider in the United States, with durable pricing and long-standing relationships across health systems, payors, and government agencies. Goldman Sachs cited "defensiveness and underappreciated growth," pointing to a high-margin air-medical mix and scale advantages, with a potential path toward low-20% EBITDA (earnings before interest, taxes, depreciation, and amortization) margins. Citi highlighted integrated-care growth and deleveraging as catalysts, while J.P. Morgan noted structural EMS demand and valuation upside.
What Could Prevent the Target From Being Reached
The obstacles are substantial. The company is still generating GAAP losses, carries meaningful leverage that it is working to reduce, and trades at a high valuation relative to current earnings. Reimbursement rates, payor mix, labor costs, and regulatory dynamics in healthcare services can pressure margins. As a newly public company with limited trading history, the shares are also exposed to broader sentiment shifts in healthcare and small-cap equities, which could compress the multiple before fundamentals catch up.
Technical Levels and Market Structure
The 52-week low near $9.00 is a key support level to watch, while the prior high around $15.98 — above which the shares have not sustained a close since the IPO — represents the first meaningful resistance zone. The $14-to-$16 area, where several cautious-to-moderate analyst targets cluster, could act as interim resistance. The $19 target sits well above both the prior high and that cluster, meaning a sustained breakout and new highs would be required.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ, and no target should be read as a timing estimate. Investors should monitor quarterly earnings and guidance, progress on deleveraging and margin expansion, payor and reimbursement developments, and any analyst target revisions. Changes in healthcare-sector sentiment and small-cap risk appetite may also influence how quickly, if at all, the valuation gap narrows.
Using Tickeron’s AI Daily Buy/Sell Signals for GMRS
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a useful complement when following names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. For a recently listed stock such as GMRS, these signals help track momentum changes alongside the fundamental picture without replacing deeper analysis.
Final Assessment
The $19 central target, derived from eight verified analyst targets averaging $18.88, sits roughly 69% above the recent price — a very large required move. Support rests on GMR's dominant U.S. EMS position, durable pricing, and the potential for meaningful margin and deleveraging progress. The principal obstacles are persistent net losses, elevated leverage, a rich valuation, and a short public track record. With targets ranging from $14 to $30, analyst views remain sharply divided, and the outcome will depend most on whether the company can translate revenue scale into consistent profitability and debt reduction. Nothing here should be read as a prediction that the stock will reach $19.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GMRS in upward trend: 10-day moving average moved above 50-day moving average on November 06, 2026
The 10-day moving average for GMRS crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on GMRS as a result. In 4 of 5 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for GMRS just turned positive on October 09, 2026. Looking at past instances where GMRS's MACD turned positive, the stock continued to rise in 1 of 2 cases over the following month. The odds of a continued upward trend are 50%.
Following a +9.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMRS advanced for three days, in 14 of 20 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 9 of 14 cases where GMRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for GMRS moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 1 similar instances where the indicator moved out of overbought territory. In 1 of the 1 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 5 of 6 cases where GMRS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
GMRS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
GMRS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.851) is normal, around the industry mean (204.532). P/E Ratio (-6.129) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.502) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. GMRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement